{"id":"active-comparator1-ezetimibe-rosuvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ezetimibe selectively inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter. Rosuvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Together, they provide complementary mechanisms to lower LDL cholesterol and reduce cardiovascular risk.","oneSentence":"This combination reduces LDL cholesterol through dual inhibition of cholesterol absorption (ezetimibe) and hepatic cholesterol synthesis (rosuvastatin).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:15.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction"}]},"trialDetails":[{"nctId":"NCT04659070","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-07-15","conditions":"Primary Hypercholesterolemia, Hypertension","enrollment":156},{"nctId":"NCT04074551","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-07-16","conditions":"Hypertension, Dyslipidemias","enrollment":145}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Active comparator1 : Ezetimibe / Rosuvastatin","genericName":"Active comparator1 : Ezetimibe / Rosuvastatin","companyName":"Hanlim Pharm. Co., Ltd.","companyId":"hanlim-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces LDL cholesterol through dual inhibition of cholesterol absorption (ezetimibe) and hepatic cholesterol synthesis (rosuvastatin). Used for Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}